Intercept Drug’s Market Standing In PBC Undermined By Safety Woes

Ocaliva Now Contraindicated In Advanced Cirrhosis

 
• By Joseph Haas
liver
Two FDA safety updates for PBC drug Ocaliva could threaten its market standing

More from Strategy

More from Business